NCT01743222View on ClinicalTrials.gov

Intralymphatic eASC Administration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions
Localized Adverse Reaction to Administration of Drug
Interventions
GENETIC

eASC

"* First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~* Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."

DRUG

Placebo

"* First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"

Trial Locations (1)

31008

Unidad de Investigación Clínica de la Clínica Universidad de Navarra, Pamplona

All Listed Sponsors
lead

Tigenix S.A.U.

INDUSTRY

NCT01743222 - Intralymphatic eASC Administration in Healthy Volunteers | Biotech Hunter | Biotech Hunter